Results 1 to 10 of about 145,743 (338)

Antibody drug conjugates [PDF]

Indian Journal of Medical and Paediatric Oncology, 2020
Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj   +7 more sources

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting [PDF]

Frontiers in Immunology, 2023
Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld, Julia Harwardt, Jan Habermann, Adrian Elter, Harald Kolmar, Harald Kolmar   +5 more
doaj   +2 more sources

Applications of Pharmacometrics in Antibody–Drug Conjugate Development [PDF]

Pharmaceutics
Antibody–drug conjugates (ADCs), which integrate a cytotoxic drug known as the payload into a tumor-targeting monoclonal antibody via a linker, have emerged as promising candidates for cancer therapy and are a new avenue for targeted cancer therapy.
Xiaoliang Cheng, Shuangmin Ji, Yonghyun Lee, Haiyan Dong   +3 more
doaj   +2 more sources

Novel Immune Checkpoint Inhibitor and Antibody–Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer [PDF]

Current Oncology
Immune checkpoint inhibitors and antibody drug conjugate combinations have revolutionized the management of patients with advanced and metastatic urothelial carcinoma, offering unprecedented survival outcomes. These treatments are now moving into earlier
Joseph Vento, Tian Zhang, Yair Lotan, Solomon Woldu, Qian Qin   +4 more
doaj   +2 more sources

CD74-Targeted Cathepsin-Inhibitor Antibody–Drug Conjugate Triggers Apoptosis in DLBCL [PDF]

Cells
Transcriptomic analyses of public datasets (TCGA and GTEx) revealed that both CD74 and Cathepsin L (CTSL) are significantly overexpressed in diffuse large B-cell lymphoma (DLBCL) compared to normal tissues, and that their expression levels are highly ...
Ihab Abd-Elrahman, Noha Khairi, Reut Sinai-Turyansky, Ivan Zlotber, Riki Perlman, Emmanuelle Merquiol, Galia Blum, Dina Ben Yehuda   +7 more
doaj   +2 more sources

HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]

Cancer Medicine
Background HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee, Adriana M. Kahn, Mariya Rozenblit, Mridula A. George, Cristina Naranjo Ortiz, Maryam B. Lustberg   +5 more
doaj   +2 more sources

Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23.
Laura Matuszewska, Caitlynn Cooper, Victoria Sattarova, Wassef Chanbour, Evan Meyer, Vania Rashidi   +5 more
doaj   +2 more sources

Antibody–drug conjugates [PDF]

Proceedings of the National Academy of Sciences, 2013
Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Beck, Alain, Reichert, Janice M.
  +8 more sources

Antibody-Drug Conjugates [PDF]

Pharmaceutical Research, 2015
Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Ashutosh A, Kulkarni, Hovhannes J, Gukasyan   +1 more
  +7 more sources

Antibody-drug conjugates

Practical oncology, 2023
This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
E.O. Stepanova, F.V. Moiseenko, V.M. Moiseyenko   +2 more
  +5 more sources